JAMES P ALLISON to Male
This is a "connection" page, showing publications JAMES P ALLISON has written about Male.
Connection Strength
0.453
-
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018 02; 6(2):189-200.
Score: 0.018
-
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunol Res. 2015 Aug; 3(8):849-54.
Score: 0.015
-
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014 Apr 07; 211(4):715-25.
Score: 0.014
-
Re: Aire-dependent thymic development of tumor-associated regulatory T cells. J Urol. 2013 Nov; 190(5):1954.
Score: 0.013
-
Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol. 2013 Jan 15; 190(2):526-30.
Score: 0.013
-
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011 Dec; 106(12):2146-53.
Score: 0.012
-
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011 Oct 24; 11(11):805-12.
Score: 0.012
-
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499.
Score: 0.011
-
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010 Aug 02; 207(8):1701-11.
Score: 0.011
-
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009 Oct 01; 69(19):7747-55.
Score: 0.010
-
Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008 Sep; 6(9):999-1003.
Score: 0.010
-
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 01; 68(15):6054-8.
Score: 0.010
-
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science. 2008 Jan 11; 319(5860):215-20.
Score: 0.009
-
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007 Dec 04; 104(49):19458-63.
Score: 0.009
-
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5.
Score: 0.009
-
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
Score: 0.007
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
Score: 0.007
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.007
-
A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med. 2003 May 26; 163(10):1165-71.
Score: 0.007
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.006
-
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
Score: 0.006
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.006
-
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
Score: 0.006
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.006
-
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
Score: 0.006
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.006
-
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
Score: 0.006
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.006
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.006
-
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020 09 17; 5(18).
Score: 0.006
-
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
Score: 0.005
-
Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
Score: 0.005
-
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019 12 16; 7(1):351.
Score: 0.005
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.005
-
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
Score: 0.005
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.005
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.005
-
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
Score: 0.005
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.005
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.005
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238.
Score: 0.005
-
Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clin Gastroenterol Hepatol. 2018 10; 16(10):1593-1597.e1.
Score: 0.005
-
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018 03 01; 24(5):1011-1018.
Score: 0.005
-
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103.
Score: 0.004
-
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017 04 27; 8:15095.
Score: 0.004
-
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
Score: 0.004
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.004
-
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
Score: 0.004
-
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
Score: 0.004
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.004
-
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24.
Score: 0.004
-
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994 Dec 15; 54(24):6477-83.
Score: 0.004
-
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27; 515(7528):577-81.
Score: 0.004
-
Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014 Apr; 106(4):dju032.
Score: 0.004
-
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44.
Score: 0.003
-
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res. 2013 Nov 15; 19(22):6112-25.
Score: 0.003
-
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013 Sep; 20(9):3106-11.
Score: 0.003
-
Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013 Mar 08; 339(6124):1219-24.
Score: 0.003
-
Augmented IL-15Ra expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol. 2012 Jun 15; 188(12):6156-64.
Score: 0.003
-
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012 Aug; 143(2):382-9.
Score: 0.003
-
Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 2012; 7(4):e35222.
Score: 0.003
-
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6187-92.
Score: 0.003
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012 Feb 08; 482(7385):400-4.
Score: 0.003
-
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A. 2012 Jan 17; 109(3):881-6.
Score: 0.003
-
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012 Jan 15; 72(2):430-9.
Score: 0.003
-
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-?1 cytokine. Immunity. 2011 Jul 22; 35(1):123-34.
Score: 0.003
-
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011 Aug; 60(8):1137-46.
Score: 0.003
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
Score: 0.003
-
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Apr 01; 116(7):1767-75.
Score: 0.003
-
Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2373-9.
Score: 0.003
-
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009 Aug; 137(2):502-11.
Score: 0.003
-
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
Score: 0.002
-
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14.
Score: 0.002
-
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol. 2007 Sep 15; 179(6):3926-36.
Score: 0.002
-
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 May 01; 175(9):926-34.
Score: 0.002
-
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24(5):442-7.
Score: 0.002
-
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173(10):6098-108.
Score: 0.002
-
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16; 22(13-14):1700-8.
Score: 0.002
-
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell. 1983 Oct; 34(3):739-46.
Score: 0.002
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7.
Score: 0.002
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7.
Score: 0.002
-
Prostate cancer: advances in immunotherapy. BioDrugs. 2003; 17(2):131-8.
Score: 0.002
-
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2001 Nov; Chapter 20:20.5.1-20.5.23.
Score: 0.001
-
Training procedures and task difficulty in brightness and position discriminations by rats. Psychol Rep. 1972 Aug; 31(1):71-6.
Score: 0.001
-
Immunogenicity of HLA antigens purified from serum. Transplantation. 1977 Jan; 23(1):7-15.
Score: 0.000